Gemcitabine-oxaliplatin regimen clinical trials
How each study uses gemcitabine-oxaliplatin regimen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the gemcitabine-oxaliplatin regimen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 24
Shanghai Zhongshan Hospital (2) · Asan Medical Center (2) · Zhejiang Cancer Hospital (2) · The First Affiliated Hospital with Nanjing Medical University (1) · Georgetown University (1) · Samsung Medical Center (1) · M.D. Anderson Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Lenvatinib (3) · Toripalimab (3) · Camrelizumab (2) · Tislelizumab (2) · Immune checkpoint inhibitors (1) · Gemcitabine (1) · Modified FOLFOX6 Regimen (1) · Docetaxel (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test gemcitabine-oxaliplatin regimen.
- Dec 2026A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Phase 2 · Fujian Cancer Hospital
- Dec 2026Golidocitinib Combined With GemOx in RR PTCLPhase 2 · Ruijin Hospital
Studies
Open first, then newest update. How each study uses gemcitabine-oxaliplatin regimen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerRecruitingPhase 2Haitao Zhao, MDNCT07854600Written as GEMOX Regimen
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06423170Written as Camrelizumab plus GEMOX
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaRecruitingPhase 2/3UNICANCERNCT06904170Written as HAIC (GEMOX)
- Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06829771Written as TQB2825 injection + GemOx
- Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic CholangiocarcinomaRecruitingPhase 2University Hospital, MontpellierNCT03364530Written as Gemcitabine-Oxaliplatin Regimen
- Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingPhase 2Ruijin HospitalNCT07279584Written as GEMOX
- Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07263360Written as Iparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib
- GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of RecurrenceRecruitingPhase 2Zhejiang Cancer HospitalNCT05557578Written as Tislelizumab combined with GEMOX (GOT) regimen
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingPhase 2Fujian Cancer HospitalNCT06654947Written as Surufatinib+Toripalimab+GEMOX
- Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBCRecruitingPhase 2Eastern Hepatobiliary Surgery HospitalNCT06013943Written as Envafolimab+Gemox
- Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT05381506Written as Orelabrutinib and Gemox
- Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCATerminatedPhase 2Peking UniversityNCT06739252Written as Gemcitabine Oxaliplatin and 5FU
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell LymphomaTerminatedPhase 1/2Antengene CorporationNCT04425070Written as GEMOX [gemcitabine+oxaliplatin]
- First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAICTerminatedPhase 2Shandong Cancer Hospital and InstituteNCT06370663Written as HAIC (GEMOX)
- Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell LymphomaTerminatedPhase 2Seoul National University HospitalNCT06941688Written as Decitabine with GemOx
- Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic CholangiocarcinomaCompletedPhase 2Shanghai Zhongshan HospitalNCT04361331Written as Lenvatinib combined with gemox
- Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingPhase 2Shanghai Zhongshan HospitalNCT05156788Written as PD-1+Lenvatinib+GEMOX
- SHR-1210 in Combination With GEMOX in Patients With Advanced BTCCompletedPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT03486678Written as SHR-1210+GEMOX
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04948788Written as Gemcitabine-Oxaliplatin
- Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX RegimenStatus unknownPhase 2Zhejiang Cancer HospitalNCT04191343Written as Toripalimab injection combined with GEMOX
See all 28 studies that test gemcitabine-oxaliplatin regimen →
Given beside what is tested · 6 — gemcitabine-oxaliplatin regimen is usual care or a partner of the new treatment
- GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced CholangiocarcinomaRecruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT05215665Written as GEMOX Regimen
- Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract CancerCompletedPhase 1/2Institut du Cancer de Montpellier - Val d'AurelleNCT02386397Written as GEMOX
- A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTCCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03092895Written as GEMOX
- Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05251662Written as GEMOX
- To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLCompletedPhase 2Boehringer IngelheimNCT02624492Written as GemOx
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaStatus unknownPhase 2Shanghai Jiao Tong University School of MedicineNCT02836847Written as GEMOX